ProQR posts early-stage trial data for liver disease candidate
Seeking Alpha ·
ProQR Therapeutics ( PRQR ) shares gained in the premarket on Thursday after the Dutch biotech announced encouraging data from a Phase 1 trial for AX-0810, an experimental therapy for liver diseases. The company said that the trial for healthy volunteers indicated
DYAX Investor Sentiment
Bullish (Long) 64% · Bearish (Short) 36%
443 participants
Related News
- Monster Beverage, Coca-Cola, lead S&P 500 consumer staples stocks by growth grades
- FedEx to buy back up to $4.15B of its debt using freight spin-off cash
- Amazon, Microsoft Face EU Gatekeeper Push
- Wedbush Issues Stark Warning on Broadcom as Google AI Chip Threat Emerges
- Broadcom Faces TPU Shakeup After 3% Drop
- Qualcomm Signs Meta as Its First Data Center Customer